カテゴリ： GlobalData, デンマーク, 企業調査

Novo Nordisk AS (NOVO B)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Novo Nordisk AS (NOVO B) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C10097
◆発行会社（調査会社）：GlobalData
◆発行日：2018年11月
◆ページ数：117
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：デンマーク
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Novo Nordisk A/S (Novo Nordisk), a subsidiary of Novo A/S discovers, develops and manufactures innovative biological medicines. It focuses at developing drugs for treating diabetes and other serious chronic conditions including hemophilia, growth disorders and obesity. The company’s product portfolio includes new-generation insulins, modern insulins, human insulins, oral antidiabetic agents, diabetes devices and others. Novo Nordisk also offers biopharmaceuticals for treating haemostasis, human growth hormone products, hormone replacement therapy and other serious chronic diseases. With subsidiaries in Europe, North America, Asia, Latin America, Africa, Middle East and Australia, the company markets its products in several countries worldwide. Novo Nordisk is headquartered in Bagsvaerd, Denmark.

Novo Nordisk AS (NOVO B) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 6
List of Figures 7
Novo Nordisk AS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Novo Nordisk AS, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9
Novo Nordisk AS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Novo Nordisk AS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11
Novo Nordisk AS, Medical Devices Deals, 2012 to YTD 2018 12
Novo Nordisk AS, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13
Novo Nordisk AS, Pharmaceuticals & Healthcare, Deal Details 16
Asset Purchase 16
Novo Nordisk to Acquire MACRILEN from Strongbridge Biopharma 16
Venture Financing 18
Affimed Therapeutics Raises US$20.2 Million In Series D Financing 18
Partnerships 20
Embark Biotech and Novo Nordisk Enter into Collaboration Agreement 20
Ossianix and Novo Nordisk Enter into Research and Option Agreement 21
Evotec Enters into Co-Development Agreement with Novo Nordisk 22
Kallyope and Novo Nordisk Enter into Research Agreement 23
BioLamina and Novo Nordisk Enter into Partnership 24
Prime Therapeutics Enters into Contract with Novo Nordisk 25
Metacrine Enters into Agreement with Novo Nordisk 26
Novo Nordisk Enters into Research Agreement with University of Oxford 27
Novo Nordisk Enters into Research Agreement with UW Medicine 28
BioClinica Enters Into Agreement With NNIT For Clinical Trial Management System 29
Humana Enters Into Research Agreement With Novo Nordisk For Diabetes 30
Novo Nordisk Enters Into R&D Agreement With Juvenile Diabetes Research Foundation For Type 1 Diabetes 31
Novo Nordisk Enters Into Co-Development Agreement With Oxford University 32
Beijing Genomics Institute Enters Into Agreement With Novo Nordisk 33
Licensing Agreements 34
Asterias Biotherapeutics Enters into Option Agreement with Novo Nordisk 34
Novo Nordisk Enters into Licensing Agreement with Epigen Biosciences 35
Novo Nordisk Enters into Research and Licensing Agreement with Lund University 36
Novo Nordisk Enters into Research and Licensing Agreement with DUKE National University Singapore Medical School 37
Novo Nordisk Enters into Licensing Agreement with University of California San Francisco 38
Novo Nordisk Enters into Licensing Agreement with EpiDestiny 39
Novo Nordisk Enters Licensing Agreement into with reMYND 40
Kiniksa Pharma Enters into Licensing Agreement with Novo Nordisk 41
Innate Pharma Enters into Licensing Agreement with Novo Nordisk 42
Novo Nordisk Enters into Licensing Agreement with Ablynx 43
Novo Nordisk Enters into Licensing Agreement with Emisphere 44
Novo Nordisk Expands Licensing Agreement with Genmab 45
Novo Nordisk Enters into Licensing Agreement with Janssen Biotech 46
Bristol-Myers Squibb Enters into Licensing Agreement with Novo Nordisk 47
Novo Nordisk Amends Licensing Agreement with Emisphere 48
Adimab Enters Into Licensing Agreement With Novo Nordisk 49
Pharmacyclics Amends Licensing Agreement With Novo Nordisk For PCI-27483 50
Caisson Biotech Enters Into Licensing Agreement With Novo Nordisk For Heparosan-Based Drug Delivery Technology 51
Caisson Biotech Expands Licensing Agreement With Novo Nordisk For Heptune Drug Delivery Technology 52
Innate Pharma Enters Into Licensing Agreement With Novo Nordisk 53
Novo Nordisk Enters Into Licensing Agreement With Kymab For Kymouse 55
Novo Nordisk Announces Licensing Agreement With National Cheng Kung University For Anti-IL-20 56
Equity Offering 57
Strongbridge Biopharma to Raise USD36.69 Million in Private Placement of Shares 57
NNIT Prices IPO for USD191 Million 58
Asset Transactions 60
Novo Nordisk Plans to Sell Inflammation Business 60
Acquisition 61
Novo Nordisk May Acquire Global Blood Therapeutics 61
Novo Nordisk to Acquire Calibrium and MB2 62
Novo Nordisk AS – Key Competitors 63
Novo Nordisk AS – Key Employees 64
Novo Nordisk AS – Locations And Subsidiaries 65
Head Office 65
Other Locations & Subsidiaries 65
Recent Developments 70
Strategy And Business Planning 70
Nov 01, 2018: Novo Nordisk to buy rights to Strongbridge’s Macrilen for $145m 70
Oct 01, 2018: Novo Nordisk to establish California manufacturing site for stem cell-based therapies 71
Sep 12, 2018: Novo Nordisk research centre opens in Oxford 12 Sep 2018 72
May 16, 2018: Novo Nordisk increases commitment to stem cell-based therapies 74
Feb 12, 2018: Novo Nordisk Plans $65M Expansion of Clayton Manufacturing Site 75
Financial Announcements 76
Nov 01, 2018: Novo Nordisk”s operating profit decreased by 6% in Danish kroner and increased by 2% in local currencies in the first nine months of 2018 76
May 02, 2018: Novo Nordisk’s operating profit decreased by 8% in Danish kroner and increased by 6% in local currencies in the first three months of 2018 77
Feb 01, 2018: Novo Nordisk increased reported operating profit by 1% in 2017 to DKK 49 billion (5% growth in local currencies) 78
Nov 01, 2017: Novo Nordisk increased reported operating profit by 5% in the first nine months of 2017 79
Aug 09, 2017: Novo Nordisk increased reported operating profit by 8% in the first six months of 2017 80
May 03, 2017: Novo Nordisk increased reported operating profit by 10% in the first three months of 2017 81
Feb 02, 2017: Novo Nordisk increased adjusted operating profit by 6% in local currencies in 2016 82
Corporate Communications 83
Oct 15, 2018: Novo Nordisk names Ludovic Helfgott executive vice president Biopharm 83
Sep 20, 2018: Novo Nordisk to lay off 400 employees in Denmark and China 84
May 16, 2017: Change in composition of the Board of Directors of Novo Nordisk 85
May 16, 2017: Change in composition of the Board of Directors of Novo Nordisk 86
Legal and Regulatory 87
Jan 11, 2017: Bernstein Litowitz Berger & Grossmann LLP Announces Securities Class Action Suit Filed Against Novo Nordisk A/S and Certain of its Senior Executives 87
Government and Public Interest 88
Jun 25, 2018: Two diabetes medications don’t slow progression of type 2 diabetes in youth 88
May 01, 2018: Novo Nordisk participates in new research project Hypo-RESOLVE to investigate hypoglycaemia and its impact in diabetes 90
Oct 31, 2017: New US study reveals key reasons why millions of people with obesity are not receiving adequate care 91
Jun 07, 2017: Lyfebulb and Novo Nordisk team up again to advance entrepreneur innovation in diabetes management 92
Apr 17, 2017: Novo Nordisk Foundation Grant 93
Product News 94
12/15/2017: Ozempic (semaglutide) recommended for approval by the European regulatory authorities 94
Dec 14, 2017: Companion Medical Announces U.S. Commercial Launch of Smart Insulin Pen System 95
12/05/2017: Ozempic (semaglutide) approved in the US 96
10/18/2017: Novo Nordisk receives positive 16-0 vote from FDA Advisory Committee in favor of approval for semaglutide 97
09/12/2017: More people treated with once-weekly semaglutide achieved reductions in both glucose and weight vs. comparator treatments 98
08/28/2018: Novo Nordisk reports positive results from SUSTAIN 6 trial 99
03/23/2018: Ozempic approved in Japan for the treatment of type 2 diabetes 100
03/20/2018: New diabetes drug may help people with obesity lose weight 101
03/05/2018: OZEMPIC now available for Canadians with type 2 diabetes 102
02/09/2018: Novo Nordisk: Ozempic (semaglutide) approved in the EU for the treatment of type 2 diabetes 103
02/05/2018: Novo Nordisk Launches Ozempic Expanding Treatment Options for Adults with Diabetes 104
Product Approvals 105
Oct 16, 2017: Novo Nordisk: FDA posts briefing materials prior to Advisory Committee meeting for semaglutide 105
Feb 28, 2017: Novo Nordisk files for regulatory approval of once-weekly semaglutide for the treatment of type 2 diabetes in Japan 106
Clinical Trials 108
Jun 23, 2018: Ozempic Provided Greater Weight Reductions for Adults With a Baseline BMI =25kg/m2 Than Those With Lower Baseline BMI 25kg/m2, in a SUSTAIN 7 Post-hoc Analysis 108
Feb 01, 2018: Semaglutide demonstrated significant reductions in blood sugar and weight compared with dulaglutide; results published in The Lancet Diabetes & Endocrinology 109
Jan 09, 2018: Ozempic approved in Canada for the treatment of adults with type 2 diabetes 110
Aug 16, 2017: Semaglutide superior to dulaglutide on glucose control and weight loss in people with type 2 diabetes in SUSTAIN 7 112
Apr 03, 2017: Once-weekly semaglutide demonstrated consistent blood glucose reductions and weight loss regardless of background oral antidiabetic treatment 113
Other Significant Developments 114
Nov 02, 2018: Novo Nordisk to lay off 1,300 employees 114
Aug 08, 2018: Novo Nordisk’s operating profit decreased by 8% in danish kroner and increased by 4% in local currencies in the first six months of 2018 115
Mar 16, 2017: CVS Health Launches Reduced Rx Savings Program to Give Patients Access to More Affordable Medications 116
Appendix 117
Methodology 117
About GlobalData 117
Contact Us 117
Disclaimer 117

List of Tables
Novo Nordisk AS, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Novo Nordisk AS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Novo Nordisk AS, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9
Novo Nordisk AS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Novo Nordisk AS, Deals By Therapy Area, 2012 to YTD 2018 11
Novo Nordisk AS, Medical Devices Deals, 2012 to YTD 2018 12
Novo Nordisk AS, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13
Novo Nordisk to Acquire MACRILEN from Strongbridge Biopharma 16
Affimed Therapeutics Raises US$20.2 Million In Series D Financing 18
Embark Biotech and Novo Nordisk Enter into Collaboration Agreement 20
Ossianix and Novo Nordisk Enter into Research and Option Agreement 21
Evotec Enters into Co-Development Agreement with Novo Nordisk 22
Kallyope and Novo Nordisk Enter into Research Agreement 23
BioLamina and Novo Nordisk Enter into Partnership 24
Prime Therapeutics Enters into Contract with Novo Nordisk 25
Metacrine Enters into Agreement with Novo Nordisk 26
Novo Nordisk Enters into Research Agreement with University of Oxford 27
Novo Nordisk Enters into Research Agreement with UW Medicine 28
BioClinica Enters Into Agreement With NNIT For Clinical Trial Management System 29
Humana Enters Into Research Agreement With Novo Nordisk For Diabetes 30
Novo Nordisk Enters Into R&D Agreement With Juvenile Diabetes Research Foundation For Type 1 Diabetes 31
Novo Nordisk Enters Into Co-Development Agreement With Oxford University 32
Beijing Genomics Institute Enters Into Agreement With Novo Nordisk 33
Asterias Biotherapeutics Enters into Option Agreement with Novo Nordisk 34
Novo Nordisk Enters into Licensing Agreement with Epigen Biosciences 35
Novo Nordisk Enters into Research and Licensing Agreement with Lund University 36
Novo Nordisk Enters into Research and Licensing Agreement with DUKE National University Singapore Medical School 37
Novo Nordisk Enters into Licensing Agreement with University of California San Francisco 38
Novo Nordisk Enters into Licensing Agreement with EpiDestiny 39
Novo Nordisk Enters Licensing Agreement into with reMYND 40
Kiniksa Pharma Enters into Licensing Agreement with Novo Nordisk 41
Innate Pharma Enters into Licensing Agreement with Novo Nordisk 42
Novo Nordisk Enters into Licensing Agreement with Ablynx 43
Novo Nordisk Enters into Licensing Agreement with Emisphere 44
Novo Nordisk Expands Licensing Agreement with Genmab 45
Novo Nordisk Enters into Licensing Agreement with Janssen Biotech 46
Bristol-Myers Squibb Enters into Licensing Agreement with Novo Nordisk 47
Novo Nordisk Amends Licensing Agreement with Emisphere 48
Adimab Enters Into Licensing Agreement With Novo Nordisk 49
Pharmacyclics Amends Licensing Agreement With Novo Nordisk For PCI-27483 50
Caisson Biotech Enters Into Licensing Agreement With Novo Nordisk For Heparosan-Based Drug Delivery Technology 51
Caisson Biotech Expands Licensing Agreement With Novo Nordisk For Heptune Drug Delivery Technology 52
Innate Pharma Enters Into Licensing Agreement With Novo Nordisk 53
Novo Nordisk Enters Into Licensing Agreement With Kymab For Kymouse 55
Novo Nordisk Announces Licensing Agreement With National Cheng Kung University For Anti-IL-20 56
Strongbridge Biopharma to Raise USD36.69 Million in Private Placement of Shares 57
NNIT Prices IPO for USD191 Million 58
Novo Nordisk Plans to Sell Inflammation Business 60
Novo Nordisk May Acquire Global Blood Therapeutics 61
Novo Nordisk to Acquire Calibrium and MB2 62
Novo Nordisk AS, Key Competitors 63
Novo Nordisk AS, Key Employees 64
Novo Nordisk AS, Subsidiaries 65

List of Figures
Novo Nordisk AS, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Novo Nordisk AS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Novo Nordisk AS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Novo Nordisk AS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Novo Nordisk AS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Novo Nordisk AS, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 9
Novo Nordisk AS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Novo Nordisk AS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11
Novo Nordisk AS, Medical Devices Deals, 2012 to YTD 2018 12

★海外企業調査レポート[Novo Nordisk AS (NOVO B)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Sabre Corporation (SABR)：企業の財務・戦略的SWOT分析
    Sabre Corporation (SABR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Wegmans Food Markets, Inc.：企業の戦略・SWOT・財務分析
    Wegmans Food Markets, Inc. - Strategy, SWOT and Corporate Finance Report Summary Wegmans Food Markets, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Milestone Scientific Inc (MLSS)-医療機器分野：企業M&A・提携分析
    Summary Milestone Scientific Inc (Milestone Scientific) is a medical device company that designs, manufactures and distributes computer controlled drug delivery instruments. The company provides medical products and dental products. Its medical products include epidurals, intra-articular injections, …
  • Venus Remedies Ltd (VENUSREM)-製薬・医療分野：企業M&A・提携分析
    Summary Venus Remedies Ltd (Venus) is a pharmaceutical company that develops, manufactures and commercializes research, herbal and generic products. The company manufactures complex formulations for oncology injections, neurology, antiseptic, pain management, anti infectives, oncology lyophilized, l …
  • Murree Brewery Co. Ltd.
    Murree Brewery Co. Ltd. - Strategy, SWOT and Corporate Finance Report Summary Murree Brewery Co. Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • BioFactura Inc：製薬・医療：M&Aディール及び事業提携情報
    Summary BioFactura Inc (Biofactura) is a manufacturer of biosimilars that discovers, develops and markets biodefense drugs and client selected novel drugs. The company provides contract services such as process development, stable cell lines, manufacturing, and others. Its stable cell line offers st …
  • Banco Hipotecario SA (BHIP3)：企業の財務・戦略的SWOT分析
    Banco Hipotecario SA (BHIP3) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Nationwide Building Society：企業の戦略・SWOT・財務分析
    Nationwide Building Society - Strategy, SWOT and Corporate Finance Report Summary Nationwide Building Society - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Anpario Plc (ANP)：企業の財務・戦略的SWOT分析
    Summary Anpario Plc (Anpario), formerly Kiotech International Plc is a producer and distributor of natural feed additives for animal health, hygiene and nutrition. The company develops products for poultry, pig, ruminant and animal feed markets that include acidifiers, essential oils, enzymes, pelle …
  • Huadian Power International Corporation Ltd (1071)：企業の財務・戦略的SWOT分析
    Huadian Power International Corporation Ltd (1071) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key …
  • Sagent Pharmaceuticals Inc：医療機器：M&Aディール及び事業提携情報
    Summary Sagent Pharmaceuticals Inc (Sagent), formerly Sagent Holding Co, a subsidiary of Nichi-Iko Pharmaceutical Co Ltd, is a biopharmaceutical company that develops and manufactures injectable products. The company offers products such as amikacin sulfate injection, USP, ampicillin and sulbactam f …
  • Bancolombia S.A.：企業の戦略・SWOT・財務情報
    Bancolombia S.A. - Strategy, SWOT and Corporate Finance Report Summary Bancolombia S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Dong-A Socio Holdings Co Ltd (000640)：企業の財務・戦略的SWOT分析
    Dong-A Socio Holdings Co Ltd (000640) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths an …
  • Innospec Inc. (IOSP)：石油・ガス：M&Aディール及び事業提携情報
    Summary Innospec Inc (Innospec) is a provider of specialty chemicals. It blends, manufactures and supplies fuel additives and other specialty chemicals. Innospec’s product portfolio includes stabilizers, detergents, cold flow improvers, lubricity improvers, corrosion inhibitors, conductivity improve …
  • Asian Hotels (North) Limited：企業の戦略・SWOT・財務情報
    Asian Hotels (North) Limited - Strategy, SWOT and Corporate Finance Report Summary Asian Hotels (North) Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Renova Therapeutics Inc：製薬・医療：M&Aディール及び事業提携情報
    Summary Renova Therapeutics Inc (Renova) is a drug development company that focuses on the development of peptide infusion therapies and gene therapy treatments for cardiovascular and metabolic diseases. The company’s pipeline products include RT-100, RT-200, RT-110, RT-400, RT-210 and RT-300. Its R …
  • PT Elnusa Tbk (ELSA)：企業の財務・戦略的SWOT分析
    Summary PT Elnusa Tbk (PT Elnusa), a subsidiary of PT Pertamina (Persero), is an oil and gas company that offers geo science services, and drilling and oilfield services. The company's geo science services include seismic data acquisition, seismic data measurement, seismic data processing, and non s …
  • BioMoti Ltd：製薬・医療：M&Aディール及び事業提携情報
    Summary BioMoti Ltd (BioMoti) is a pharmaceutical company that offers cancer therapeutics that develops platform drug delivery technologies. The company provides products such as Oncojans a class of immunotherapeutic drug-loaded particles to target and gain entry into the tumour vasculature and canc …
  • Kolorfusion International Inc：企業の戦略的SWOT分析
    Kolorfusion International Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produ …
  • Jack in the Box Inc (JACK)：企業の財務・戦略的SWOT分析
    Jack in the Box Inc (JACK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆